X

Stay Connected

Sign Up for Updates

network1.png

PPA strives to improve patient health, advance medical innovation and fuel economic growth.

LEARN MORE
network1.png

The PhRMA Foundation supports the research and career endeavors of scientists in drug discovery and development.

LEARN MORE
network1.png

Access Better Coverage educates consumers about the ABCs of health coverage and access to medicines.

LEARN MORE
network1.png

We Work For Health aims to increase awareness by uniting workers throughout the industry.

LEARN MORE
network1.png

Patent protection should always be considered by an inventor during the initial stages of their invention.

LEARN MORE
logo_white_MyOldMeds-New-1.png

Working to spread awareness and education about the importance of secure drug disposal.

LEARN MORE
LTAC_NEW21.png

Many Americans are struggling to afford their medicines and have important questions about their medicine costs. Let's Talk About Cost addresses these questions.

LEARN MORE
logo_white_LTAM.png

There are a lot of conversations in Washington about how to change Medicare Part D, but they aren't always focused on what seniors care about most: affordability and predictability.

LEARN MORE
We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

Growth in innovative, value-based contracts holds promise for the health system and for patients

By Katie Koziara  |    September 24, 2020
The extraordinary financial pressure COVID-19 is creating for the U.S. economy underscores the need for a renewed push toward a more value-driven health care system that prioritizes patient access...   Read More

Guest post: Value-based agreements can improve outcomes and even save patients money at the pharmacy counter

By Guest Contributor  |    November 7, 2019
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The Catalyst welcomes guest...   Read More

New data show how ICER’s value framework could prevent or delay access to treatments for Medicaid patients across the country

By Katie Koziara  |    November 4, 2019
A new analysis from Xcenda applied the Institute for Clinical and Economic Review’s (ICER) value assessments to state Medicaid programs in California, Massachusetts, Maryland, Nevada and New York....   Read More

5 Ways to improve ICER’s value assessment framework

By Lauren Neves  |    June 20, 2019
The Institute for Clinical and Economic Review’s (ICER) recently made a call for suggestions and feedback on how to improve its value assessment framework and methods. We are a strong supporter of...   Read More

Assessing value top of mind at ISPOR 2019

By Samantha Dougherty  |    June 5, 2019
As we move toward a value-driven health care system, the focus should be on outcomes that matter most to patients, such as how medicines make patients feel, whether they can return to work or how...   Read More

Event tomorrow: Leaders convene to discuss solutions to advance value-driven health care

By Katie Koziara  |    October 2, 2018
Tomorrow, October 3, PhRMA will convene health care leaders for a discussion on how we can move our health care system toward one focused on value rather than volume, ensuring patients can access...   Read More

New whitepaper identifies reasons why ICER’s cost-effectiveness analyses are not useful for payers

By Lauren Neves  |    September 19, 2018
A new whitepaper authored by Bruce Pyenson, F.S.A., M.A.A.A. and colleagues from Milliman explains why Institute for Clinical and Economic Review (ICER) cost-effective analyses (CEAs) will not be...   Read More

Guest post: Developing new payment models to ensure patients have access to high-investment therapies

By Guest Contributor  |    September 6, 2018
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The Catalyst welcomes guest...   Read More

Number of value-based contracts continues to rise

By Michelle Drozd  |    August 27, 2018
The list of publicly announced value-based contracts (VBCs) – also called results-based contracts – between biopharmaceutical companies and health plans continued to grow over the last quarter –...   Read More

ICER’s budget impact threshold: Sounding a false alarm on affordability and access

By Randy Burkholder  |    July 24, 2018
If a home inspector found “wide and unpredictable variation” in your smoke detectors, would you want to fix them?   Read More

Search the Catalyst

View Posts by Topic

see all

View Posts by Contributor

View Posts by Date

see all

Subscribe to Email Updates

Most Popular Posts

Most Popular Posts

Pharmaceutical Research and Manufacturers of America®
950 F Street, NW Suite 300, Washington, DC 20004